Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Hims stock took a hit late Monday after the company reported surprise losses and issued a light guide for the year. The post Hims Tumbles On Surprise Losses, Light 2026 Outlook appeared first on Investor’s Business Daily.
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company’s obesity drugs, further entrenching itself in the GLP-1 space. The post Hims & Hers Surges On ‘Surprising And Inevitable’ Deal With Eli Lilly appeared…
Novo stock popped early Wednesday on better-than-expected third-quarter sales and profit thanks to resounding beats from its GLP-1 drugs. The post Novo Surges 5% After Walloping Expectations On The Back Of Its GLP-1 Drugs appeared first on Investor’s Business Daily.
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound. The post Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance appeared first on Investor’s Business Daily.
Eli Lilly’s next-generation weight-loss drug, retatrutide, trounced Novo’s Ozempic in a head-to-head study, the company said Wednesday. The post Eli Lilly’s Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test appeared first on Investor’s Business Daily.
Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn’t even hit the market. The post Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug appeared first on Investor’s Business Daily.
The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs. The post Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market appeared first on Investor’s Business Daily.
Eli Lilly is Tuesday’s IBD Stock Of The Day. Shares are staring down two potential entries as the weight-loss kingpin gains on Novo Nordisk. The post Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills…
Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who’ve undergone bariatric surgery. The post A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High. appeared first on Investor’s Business Daily.
